by Jason Heaviland | Jan 12, 2026
Payload to Patient: Metabolomics in ADC and Immuno-Oncology In this episode of the ChatGJP series, Panome Bio CSO Dr. Gary J. Patti joins Chris Eden to explore real-world applications of metabolomics in antibody–drug conjugates (ADCs) and immuno-oncology. The...
by Jason Heaviland | Dec 4, 2025
Integrated Multi-Omic Analysis of KRAS-Driven Colorectal Cancer This poster presents an integrated multi-omic analysis of colorectal cancer models driven by the KRAS mutation. By combining global metabolomics, proteomics, phosphoproteomics, and transcriptomics, the...
by Jason Heaviland | Dec 3, 2025
From Metabolism to Mechanism, Profile PRMT5 Activity in Cancer Profile PRMT5 activity with precise SDMA/ADMA quantification and full methionine cycle coverage. Support inhibitor development, patient stratification, and tumor profiling.
by Jason Heaviland | Nov 24, 2025 | Uncategorized
How Metabolomic Biomarkers Could Save PRMT5 Drug Development The PRMT5 inhibitor field represents one of the most expensive lessons in modern oncology drug development. Despite massive investments – including Bristol Myers Squibb’s $4.8 billion acquisition...
by Jason Heaviland | Nov 24, 2025 | Uncategorized
Two Targets, One Pathway: The Metabolomic Logic Behind MAT2A/PRMT5 Combination Therapies The next breakthrough in cancer treatment may come from attacking two targets within the same metabolic pathway. MAT2A and PRMT5 inhibitor combinations represent a new paradigm in...
